| RRC ID |
81794
|
| Author |
Osada N, Kikuchi J, Okada Y, Matsuoka S, Morishita K, Nakasone H, Furukawa Y.
|
| Title |
Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells.
|
| Journal |
PLoS One
|
| Abstract |
Adult T-cell leukemia/lymphoma (ATL) develops from the infection of T cells with human T lymphotropic virus type 1 (HTLV-1). There are an estimated 5-20 million HTLV-1 carriers worldwide and the patients are frequently observed in subtropical Africa, the Caribbean, Middle East, South America, and South West Japan. The prognosis of ATL remains dismal due to rapid acquired resistance to treatment with cytotoxic chemotherapeutic agents. In particular, the development of novel therapies for relapsed or refractory (R/R) ATL is an unmet need. Previous clinical trials revealed that bendamustine (BDM) was effective as the first-line treatment for indolent lymphoma and R/R cases of diffuse large B-cell lymphoma. Its major advantage is that it has few side effects such as hair loss and peripheral neuropathy, and does not impair the quality of life. However, its efficacy has not been verified for ATL in pre-clinical or clinical studies. In this study, we have shown the cytotoxicity of BDM alone and in combination with novel agents including the histone deacetylase (HDAC) inhibitor tucidinostat, the enhancer of zeste homolog 1/2 (EZH1/2) dual inhibitor valemetostat, and the Bcl2 family inhibitor ABT-737. The combined in vitro effects of BDM and tucidinostat were reproduced in a murine model without any obvious hematological toxicity. Our present results suggest that the combination of tucidinostat and BDM could additively prolong the survival of patients with R/R progressive ATL. The efficacy and safety of this combination are thus worthy of investigation in clinical settings.
|
| Volume |
19(9)
|
| Pages |
e0309533
|
| Published |
2024-1-1
|
| DOI |
10.1371/journal.pone.0309533
|
| PII |
PONE-D-24-23694
|
| PMID |
39348376
|
| PMC |
PMC11441677
|
| MeSH |
Animals
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Apoptosis / drug effects
Bendamustine Hydrochloride* / pharmacology
Bendamustine Hydrochloride* / therapeutic use
Cell Line, Tumor
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylase Inhibitors / therapeutic use
Humans
Leukemia-Lymphoma, Adult T-Cell* / drug therapy
Leukemia-Lymphoma, Adult T-Cell* / pathology
Mice
Xenograft Model Antitumor Assays
|
| Resource |
| Human and Animal Cells |
ATN-1(RCB1440) |
